Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of S-1226 in Healthy Volunteers
NCT02616770Phase 1Completed
- Sponsor
- SolAeroMed
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Device-based Delivery
01
Overview
Phase 1, randomised, double-blind trial of S-1226 in asthma (6 arms), sponsored by SolAeroMed. Primary endpoint: Safety and tolerability to S-1226 assessment. Started Mar 2014; status: completed.
02
Drugs
S-1226
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02616770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616770.